Analysis of Genomic Drivers of Discordant Risk Classifications in Prostate Cancer - Michael Zelefsky
Analysis of Genomic Drivers of Discordant Risk Classifications in …
2 months ago
urotoday.com
Survival Gap in Latin American Cancer Care: Public vs Private Systems - Fernando Maluf
Survival Gap in Latin American Cancer Care: Public vs Private Sy…
1 month ago
urotoday.com
IBCG Recommendations for Intermediate-Risk NMIBC Definitions and Management - Roger Li
IBCG Recommendations for Intermediate-Risk NMIBC Definitio…
2 weeks ago
urotoday.com
Differences in Genomic Alteration Frequencies by Race in Metastatic Prostate Cancer - Kara Maxwell
Differences in Genomic Alteration Frequencies by Race in Metastati…
3 months ago
urotoday.com
GTB-5550: A Tri-specific NK Cell Engager Designed to Target B7-H3 - Nicholas Zorko
GTB-5550: A Tri-specific NK Cell Engager Designed to Target B7-H…
2 weeks ago
urotoday.com
PSA Thresholds in mHSPC: What VA Data Reveals About Optimal Targets - Stephen Freedland
PSA Thresholds in mHSPC: What VA Data Reveals About Optimal T…
2 months ago
urotoday.com
Phase Ib/II Trial Combines Ciforadenant with Ipilimumab and Nivolumab in Frontline Kidney Cancer - Kathryn Beckermann
Phase Ib/II Trial Combines Ciforadenant with Ipilimumab and …
1 month ago
urotoday.com
Investigational Therapies Target STEAP1 and DLL3 in Advanced Pr…
2 weeks ago
urotoday.com
Real-World Analysis of Nadofaragene Firadenovec and Be…
1 month ago
urotoday.com
Study of PSA Testing Perceptions Among Black Patients and Their P…
1 month ago
urotoday.com
COTRIMS Trial Shows High Cure Rates with RPLND in Stage IIA/B S…
3 months ago
urotoday.com
PARP Inhibitors in Prostate Cancer: A Decade of Development and the …
1 month ago
urotoday.com
Association of PSA Trajectories with Survival in mHSPC from ARASEN…
1 week ago
urotoday.com
Targeting NSD2 to Reverse Treatment Resistance in Advance…
3 weeks ago
urotoday.com
Targeting SPP1+ Macrophages and the Adenosine Pathway to Boost …
1 month ago
urotoday.com
Moving Beyond DNA: The Role of Early, Multi-Modal Genomic Testin…
3 weeks ago
urotoday.com
Health-Related Quality of Life Outcomes from the NIAGARA Tria…
1 month ago
urotoday.com
ARTISAN Trial: Evaluating Lead-212 PSMA Therapy for Advanced Pros…
1 month ago
urotoday.com
CORE-008 Cohort B Investigates Cretostimogene Grenadenorepve…
1 week ago
urotoday.com
Phase 1B Trial Combines Xaluritamig with Hormone Therap…
3 weeks ago
urotoday.com
ADSTILADRIN® in Patients With High-Risk, BCG Unresponsive NMI…
Mar 22, 2020
urotoday.com
The Benefit of Adding Short-Term ADT to Prostate Bed Salvage Radi…
Nov 15, 2022
urotoday.com
Phase III PSMAfore Trial: Final Survival and Safety Data in mCRP…
3 months ago
urotoday.com
Discussion on Treatment Sequencing for mCRPC After Prog…
3 months ago
urotoday.com
Implementing Systemic Biomarker Testing for Metastatic Prostate Ca…
6 months ago
urotoday.com
Highlights in Prostate Cancer Treatment Advances from ESMO 2…
Nov 5, 2024
urotoday.com
Bone Health Management for Advanced Prostate Cancer - Fred …
Nov 8, 2023
urotoday.com
See more videos
Static thumbnail place holder